[Comment] Can the positive findings from POD1UM-304 improve patient care worldwide?

In the past decade, the treatment landscape for non-oncogene-addicted non-small-cell lung cancer (NSCLC) has changed substantially. Immune checkpoint inhibitors, either alone or combined with chemotherapy (the latter especially in tumours with PD-L1 expression of less than 50%), are recommended by clinical guidelines as first-line treatment regimens.1 These recommendations are supported by multiple phase 3, randomised clinical trials that show both the efficacy and the safety of immune checkpoint inhibitor-based treatment regimens.